Fiala

Peptide library › Digestive health

PN-943

In clinical trialsDigestive health

Experimental gut-targeted tablet for ulcerative colitis that blocks immune cells from entering the bowel.

What people use it for

What PN-943 does in the body

An oral peptide that blocks α4β7 integrin, the 'address tag' some immune cells use to home in on the gut. It works on the same target as the injected drug vedolizumab.

Strength of evidence

Limited: its first controlled trial missed its main goal.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

Investigational. Not approved by the FDA.

How it's taken

Route: Tablet by mouth (in trials)

How long it lasts (half-life): Designed to act mainly inside the gut

Keep track of PN-943 privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open PN-943 in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Digestive health